About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Podcasts
Discussing AxSpA: Long-term etanercept response and real-world effectiveness of tofacitinib and adalimumab
Podcasts
Discussing RA: April 2024
Publications
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
Publications
Guselkumab provides durable improvement across psoriatic arthritis disease domains: Post hoc analysis of a Phase 3, randomised, double-blind, placebo-controlled study
Publications
Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized Phase 2 trial
Publications
Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the Phase 3 KEEPsAKE1 randomized clinical trial
Publications
Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: A systematic review and meta-analysis
Podcasts
Author Interview: Professor Maria Antonietta D’Agostino, 2024
Publications
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Podcasts
Author Interview: Professor Dennis McGonagle, 2024
Publications
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
Publications
"I couldn't carry on taking a drug like that": A qualitative study of patient perspectives on side effects from rheumatology drugs
Publications
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: A post hoc analysis of a Phase 3b/4 randomised safety study
Podcasts
Discussing AxSpA: Secukinumab retention over time & sacroiliac joint improvements between DMARDs
Publications
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Real-world data from the BIOBADASER registry
Podcasts
Author Interview: Dr Jürgen Rech, 2024
Podcasts
Discussing PsA: Long-term safety of ixekizumab & bimekizumab treatment in a TNFi-IR population
Podcasts
Discussing RA: March 2024
Publications
Comparative effectiveness of tofacitinib and adalimumab in axial spondyloarthritis: A real-world clinical context multicenter study
Publications
Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-Year data from SELECT-COMPARE
Publications
Long-term etanercept response for patients with radiographic axial spondyloarthritis based on achievement of early, intermediate, or late responses during index studies
Publications
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
Podcasts
Discussing AxSpA: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment
Publications
Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients
Publications
Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA
Podcasts
Discussing RA: February 2024
Podcasts
Discussing PsA: Clinical Response to Guselkumab & Sequential Lines of b/tsDMARDs
Publications
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial
Publications
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): Data from the French Multicentre Retrospective FORSYA Study
Publications
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Publications
Efficacy of Pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Podcasts